UN Atomic Boss Achieves Gender Parity. Just Don't Call It DEI
The head of the United Nations atomic watchdog distanced himself from policies promoting diversity, equality and inclusion in the workplace even as he sought to promote the agency's successful efforts in hiring more women.
Rafael Mariano Grossi, a top candidate to become the UN's next secretary general, achieved gender parity at the Vienna-based International Atomic Energy Agency in record time, adding hundreds of female scientists and technicians to the payroll over the last five years. Women now slightly outnumber men for the first time at the agency, best known for monitoring nuclear activities in global trouble-spots, ranging from Iran to Ukraine.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
At least 2,680 killed in Haiti unrest so far this year: UN
At least 2,680 people were killed in Haiti in the first five months of the year, the United Nations said Friday, voicing alarm at widening gang violence. Haiti is the poorest country in the Western hemisphere with swathes of the country under the control of rival armed gangs who carry out murders, rapes and kidnappings. UN human rights chief Volker Turk said the crisis had plummeted to a new low, with gangs extending their reach beyond the coastal capital Port-au-Prince into central regions. The UN Human Rights Office said at least 2,680 people had been killed between January 1 and May 30, including 54 children. Those figures were from information it has been able to verify, but it said the true toll would likely be far higher. At least 957 others had been wounded and 316 kidnapped for ransom, it added. Sexual violence by gangs and their recruitment of children was also still rising. "Alarming as they are, numbers cannot express the horrors Haitians are being forced to endure on a daily basis," Turk said in a statement. "I am horrified by the ever-increasing spread of gang attacks and other human rights abuses beyond the capital, and deeply concerned by their destabilising impact on other countries in the region." With law enforcement struggling to restore security, mobs and self-defence groups were taking matters into their own hands, leading to even more human rights abuses, he added. Turk cited deadly clashes between gangs and so-called self-defence groups, including one in which at least 25 were killed with machetes. While the country is nominally run by a transitional government, there has been a fresh surge of violence since February, with gangs pressing into previously safe areas. Gangs control 85 percent of Port-au-Prince, according to the UN, and have stepped up attacks on areas not yet under their control. A record number of people -- almost 1.3 million -- have been forced to flee their homes in Haiti due to violence, the UN's migration agency said Wednesday. Turk said the coming months would test the international community's ability to take stronger action to stabilise Haiti and the wider region. rjm/vog/jj
Yahoo
35 minutes ago
- Yahoo
UN Security Council to discuss Israeli strikes on Iran
The UN Security Council is set to convene in New York later on Friday following Israel's heavy attacks on Iran, according to diplomatic sources. The UN's most powerful body is to meet at 3 pm (1900 GMT) at the request of Russia, backed by China. The council is usually unable to take decisions regarding the Middle East due to the veto power of Israel's ally, the United States. Earlier on Friday, Iran had formally requested an emergency meeting of the Security Council. According to a report by the Iranian state-run IRNA news agency, Iran sent an urgent letter condemning Israel's strikes on nuclear facilities and the killing of military personnel, and calling for the council to respond to what Iran described as the "obvious aggression of the Zionist regime."
Medscape
an hour ago
- Medscape
Immune Modulation in MDS: Our Core Strategies Need to Change
MILAN — Immune-based treatments continue to fall short in myelodysplastic syndromes (MDS). Now, experts from the European Hematology Association's (EHA) Specialized Working Group on MDS here at the EHA 2025 Congress are reevaluating their core strategies, from clinical trial endpoints to patient selection and timing. The researchers are suggesting the need for a shift in how these therapies are developed and deployed, as new data suggests that current benchmarks might be missing meaningful responses and that immune dysfunction in MDS can evolve over time. MDS are a heterogeneous group of clonal myeloid stem and progenitor cell disorders marked by ineffective hematopoiesis, cytopenias, and a risk of progression to acute myeloid leukemia. Immune dysregulation is thought to be a key driver in MDS pathogenesis, raising hopes that modulating immune responses within the bone marrow niche could alter disease trajectory. Yet, despite numerous attempts, immune-based interventions have largely failed to yield meaningful clinical results. Choosing the Right Endpoints Currently, few therapies targeting inflammation and immune activation are approved for MDS — namely antithymocyte globulin, with or without cyclosporine A, lenalidomide, and luspatercept. However, a growing list of investigational agents is under study, including cytokine inhibitors, signaling pathway inhibitors, immune checkpoint inhibitors, bispecific and trispecific antibodies, and chimeric antigen receptor cell-based therapies. Anne Sophie Kubasch, MD Anne Sophie Kubasch, MD, a hematologist at the University Medical Hospital Leipzig, Germany, presented preliminary findings from two trials by the German MDS Study Group: the phase 2 CANFIRE trial of the IL-1Beta inhibitor canakinumab and the LUCAS trial of the IRAK4 inhibitor emavusertib. The CANFIRE trial enrolled 11 patients treated for 6 months, while LUCAS included 36 patients treated for 4 months. Both studies failed to meet their primary endpoint, hematologic improvement in erythroid cells per International Working Group (IWG) 2018 criteria, by the end of the treatment period. Despite this, Kubasch noted that several patients opted to continue treatment due to perceived clinical benefit, such as reduced fatigue or general improvement. Some also showed biomarker changes or delayed hematologic responses. These findings led her to question whether hematologic improvement in erythroid cells is the most appropriate efficacy endpoint for immunomodulatory agents. 'We can argue that current IWG endpoint criteria are too rigid for immune modulation trials,' she said. 'Late or gradual responses may go undetected.' Kubasch suggested that future trials should incorporate patient-reported outcomes and quality-of-life metrics as co-primary endpoints. 'We may focus on composite endpoints combining various parameters, such as hematologic trends, biomarker shifts, molecular remission or stability, and, of course, patient-reported benefits.' Selecting the Right Patients A second key question, Kubasch said, is whether the right patients are being selected for immunotherapy. She cited a recent transcriptomic analysis of bone marrow CD34+ cells from 183 MDS patients that identified two immune subtypes based on the expression of six genes — including IRAK4 , the target of emavusertib. These subtypes were called hyperactive (HIC) and moderate (MIC) immune clusters. The HIC group had greater activation of immune-related pathways and higher infiltration of natural killer cells and M1 macrophages. 'We might be treating the wrong immune subgroup with immunomodulators,' she said, hypothesizing that it's possible that only MIC patients were being enrolled in their trials, contributing to negative results. She proposed a stepwise stratification approach: Baseline assessment (low-risk MDS diagnosis, anemia, transfusion burden) Genetic stratification (cytogenetics, mutations, resistance markers) Immune transcriptomic profiling (HIC/MIC clustering) 'Selective inclusion of patients with immune activation, such as those with an HIC profile, is essential,' she concluded. Targeting the Right Immune Alterations Valeria Santini, MD, associate professor of hematology at the University of Florence Medical School, Italy, focused her remarks on immunosuppressive therapy, a long-used but inconsistently effective strategy in MDS. To re-evaluate its role, Santini reviewed older literature — what she called 'archaeological digging.' She showed that complete responses and survival benefits are achievable in some patients, albeit rarely. Importantly, she emphasized that immune dysfunction in MDS is dynamic. 'It changes during the course of the disease,' she said. Therefore, precise immune profiling at both the subtype and patient level is needed. Optimization of immunosuppressive therapy is hampered by the lack of prospective randomized trials, heterogeneity in study populations, poor characterization of immune abnormalities, and the need for integration with novel agents. 'It is not one cure for all,' she said. 'By selecting patients, we might be more successful than in the past.' Finding the Right Drugs and the Right Timing Lionel Adès, MD, PhD, professor of hematology at Saint-Louis Hospital, Paris, France, commented to Medscape Medical News that, while the biological rationale for immune modulation is strong, clinical evidence remains weak. Lionel Adès, MD, PhD 'Maybe we don't have the right drugs or combinations. Maybe we're using them too late in the disease course,' he said. Immune dysregulation might play a role early in MDS, but by the time patients are treated, it could be too late to alter the disease with immune-targeted agents. Moreover, Adès noted that immune therapies often require extended treatment periods before activity can be detected, while traditional MDS trial endpoints focus on earlier timepoints. 'If a drug appears completely ineffective, it's not ethical to keep a patient on trial for a year just to see if something happens,' he said. Still, he remains cautiously optimistic. He pointed to the EHA-sponsored i4MDS Consortium, which aims to deepen understanding of MDS immunobiology, and to data from the STIMULUS MDS 2 study presented during the session by Amer Zeidan, MBBS, MHS, of Yale University, New Haven, Connecticut. That study evaluated the TIM-3 immune checkpoint inhibitor sabatolimab plus azacitidine as a first-line therapy in MDS. Although the trial failed to show a survival advantage overall, subgroup analysis revealed a benefit among female patients. 'This is something very interesting,' Adès said. 'It's something we didn't look at before, because we never thought survival could differ between male and female MDS patients.' While sabatolimab development has since been discontinued, other agents targeting the same pathway remain in the pipeline. 'This finding could be valuable for stratifying future trials by sex,' he said. Kubasch reported relationships with BMS, Curis, Jazz, Johnson & Johnson, and Novartis. Santini reported serving on advisory boards for AbbVie, Ascentage, BMS, Geron, GSK, Keros, Novartis, Servier, and Takeda. Adès disclosed research support from BMS/Celgene and AbbVie, and advisory roles with AbbVie, Amgen, BMS, Jazz, Novartis, Roche, and Takeda.
